Systemic immune suppression in glioblastoma: the interplay between CD14(+)HLA-DR(lo/neg) monocytes, tumor factors, and dexamethasone

Patients with glioblastoma (GBM) exhibit profound systemic immune defects that affect the success of conventional and immune-based treatments. A better understanding of the contribution of the tumor and/or therapy on systemic immune suppression is necessary for improved therapies, to monitor negativ...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Gustafson, Michael P., Lin, Yi, New, Kent C., Bulur, Peggy A., O'Neill, Brian Patrick, Gastineau, Dennis A., Dietz, Allan B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2010
Konular:
Basic and Translational Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940665/
https://ncbi.nlm.nih.gov/pubmed/20179016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq001
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller